GET DAILY SIGNALSAccuray (ARAY) Q1 Fiscal 2027 Earnings Show 8% Revenue Decline Amid Product Headwinds
Key Takeaways
- Accuray reported first quarter fiscal 2027 net revenue of $86.5 million, down 8% year over year, as product revenue continued to face pressure.
- Service revenue rose 4% to $59.2 million, supported by a growing installed base and pricing actions.
- Net income was $10.1 million, or $0.07 per diluted share, driven largely by a $59.6 million non-cash gain on debt extinguishment, partially offset by a $35.4 million goodwill impairment.
- Excluding those items, the company posted a net loss of $14.0 million, or $0.10 per diluted share, an improvement from the $0.18 loss a year earlier.
- Gross product orders fell to $19.8 million from $39.6 million, producing a book-to-bill ratio of 0.7, while order backlog declined roughly 31% to $272.0 million.
- The company continues not to provide formal revenue or Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) guidance for fiscal 2027.
Putting the Quarter in Context
Accuray's first quarter fiscal 2027 report arrives at an important juncture in the radiation therapy company's ongoing transformation. Following a fiscal 2026 that featured restructuring, cost cuts, and a financing deal with TCW, I am watching closely to see if operational improvements can translate into stronger product demand. The results underscore a clear divide between a stable, high-margin service business and a product segment still dealing with geopolitical tensions and softness in China. With order volumes and backlog drawing attention, this update provides useful insight into whether cost discipline and service economics can counter ongoing demand challenges and support a steadier financial position.
Breaking Down the Reported Results
Accuray posted total net revenue of $86.5 million for the first quarter of fiscal 2027, down $7.4 million, or 8%, from the prior-year period and down 7% on a constant currency basis. That figure came in below the consensus estimate of roughly $95.8 million. Service revenue increased 4% year over year to $59.2 million, up 5% on a constant currency basis, helped by pricing actions and expansion of the global installed base. Product revenue fell to $27.3 million from $37.2 million, reflecting geopolitical factors and market conditions in China.
Net income reached $10.1 million, or $0.07 per diluted share. This result was shaped significantly by a $59.6 million non-cash gain on debt extinguishment from the July 2026 financing transaction and a $35.4 million non-cash goodwill impairment charge. Stripping out both items, the company reported a net loss of $14.0 million, or $0.10 per diluted share, compared with a net loss of $0.18 per diluted share in the prior-year quarter. Adjusted EBITDA improved to $2.5 million from a negative $4.1 million a year earlier. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
How the Market Reacted
Investor sentiment around ARAY has stayed cautious, with shares facing notable pressure over the past year as product revenue and order trends weakened. While the headline EPS of $0.07 beat the consensus estimate of a $0.07 loss, the outperformance stemmed from non-cash, one-time items rather than underlying operations. The revenue miss and steep drop in gross product orders are likely to influence market interpretation more than the headline figure. The 0.7 book-to-bill ratio and backlog roughly 31% lower than a year ago point to weaker near-term demand visibility, which aligns with the cautious tone seen in recent trading.
What to Watch Going Forward
Looking ahead, the first area to monitor is whether product orders and revenue can stabilize. Gross product orders were cut roughly in half year over year, and the 0.7 book-to-bill ratio shows the company drawing down backlog faster than it is rebuilding it. A sustained recovery in orders, especially outside China, will be key to restoring revenue growth.
Next, track the services business trajectory. With an installed base now exceeding 1,100 systems and more than $230 million in recurring annual revenue, service growth and margin expansion offer a more durable base. Management noted a 410-basis-point improvement in service gross margin during the quarter, and further progress here could bolster profitability even if product revenue remains soft.
Geopolitical and tariff developments, particularly in China and the Middle East, also warrant attention, as they have limited demand and factored into the decision to withhold formal fiscal 2027 guidance. Finally, keep an eye on the balance sheet. The completed TCW financing steps, including the $15 million cash investment and exchange of $40 million of term loan debt for convertible preferred equity, aim to reduce leverage and improve liquidity, providing more room to execute the turnaround plan. From what I see, these factors will shape the path ahead.
Enhancing Research with AI Tools
When evaluating names like ARAY, I often turn to Tickeron’s AI Screener for a structured way to review technical patterns, fundamentals, and industry comparisons. It helps surface ideas that align with specific criteria without the need for fully manual screening, which supports more efficient analysis in my process.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ARAY sees its Stochastic Oscillator recovers from oversold territory
On November 02, 2026, the Stochastic Oscillator for ARAY moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 70 instances where the indicator left the oversold zone. In 58 of the 70 cases the stock moved higher in the following days. This puts the odds of a move higher at over 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ARAY's RSI Indicator exited the oversold zone, 36 of 45 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on ARAY as a result. In 76 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for ARAY just turned positive on November 02, 2026. Looking at past instances where ARAY's MACD turned positive, the stock continued to rise in 36 of 48 cases over the following month. The odds of a continued upward trend are 75%.
Following a +12.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARAY advanced for three days, in 156 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
ARAY moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ARAY crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARAY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for ARAY entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.411) is normal, around the industry mean (4.170). P/E Ratio (-0.359) is within average values for comparable stocks, (1.500). Projected Growth (PEG Ratio) (2.060) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (0.070) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. ARAY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of medical equipment
Industry MedicalNursingServices
Advertisement